Navigation Links
Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients
Date:6/7/2012

Berlin, Germany, June 7 2012: Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem cell transplantation (HSCT) results in better long term survival than conventional treatment for patients with poor prognosis early diffuse cutaneous systemic sclerosis.

The ASTIS (Autologous Stem Cell Transplantation International Scleroderma) trial enrolled more than 150 patients between 2001 and 2009, and randomised patients to the HSCT arm or to intravenous pulse cyclophosphamide treatment. As of May 1, 2012, significantly more deaths have occurred in the conventional treatment group. Half of the deaths in the HSCT group occurred early and were deemed treatment-related according to an independent data monitoring committee. In the conventional treatment group in contrast, none of the deaths were deemed to be treatment-related; but more deaths occurred later and most were related to progressive disease.

"Systemic sclerosis is a debilitating disease that can lead to heart, lung or kidney failure and premature death, especially in patients who have the diffuse cutaneous form of the condition, where skin thickening is more generalised and involvement of vital organs more common. The ASTIS study shows that such patients may benefit from early intensive immunosuppressive treatment," said Professor Jaap van Laar from Newcastle University, Professor Dominique Farge, Assistance Publique Hopitaux de Paris (Sponsor in France, Paris 7 University) and Professor Alan Tyndall from Basel University, on behalf of their colleagues from the EBMT EULAR Scleroderma Study Group. "These initial results are very encouraging and will help identify patients who benefit from stem cell transplantation."

The ASTIS trial was a unique collaborative project of 27 multidisciplinary teams from 10 countries conducted under the auspices of two leading organisations in the respective fields, the European Group for Blood and Marrow Transplantation (EBMT; www.ebmt.org) and the European League Against Rheumatism (EULAR;www.eular.org). The primary endpoint of the trial was event-free survival, defined as survival until death or development of major organ failure.

Systemic sclerosis is a rare but severe autoimmune systemic connective tissue disease*. Increased fibroblast activity results in abnormal growth of connective tissue which causes vascular damage and fibrosis of the skin, gastrointestinal (GI) tract and other internal organs**. Characteristics of systemic sclerosis include vasomotor disturbances; fibrosis; subsequent atrophy of the skin, subcutaneous tissue, muscles, and internal organs and immunologic disturbances*. Systemic sclerosis is estimated to occur in 2.3-10 people per one million*. Diffuse cutaneous systemic sclerosis cases make up 30% of all systemic sclerosis cases and involve the upper arms, thighs and trunk**. Lung fibrosis and pulmonary hypertension are important causes of mortality in these patients and there is no curative treatment available so far*.


'/>"/>
Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Fewer platelets could be used for some cancer and bone-marrow transplantation patients
2. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
3. Living donor exchange poses new option for liver transplantation
4. Cell Transplantation Eyed as Treatment for Cerebral Palsy
5. Cedars-Sinai heart transplantation tip sheet
6. Study examines global availability of treatment involving transplantation of blood stem cells
7. African-Americans and women are less likely to undergo bone marrow transplantation
8. The experience of arterial reconstruction in adult-to-adult living donor liver transplantation
9. Combination of Meniscus Allograft Transplantation and Repair of Articular Cartilage May Slow the Progression of Arthritis in the Knee
10. Stem cell transplantation of therapy-resistant chronic leukemia successful
11. New transplantation criteria for liver cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 2016 , ... Fertility Centers of New England announced today the opening of ... Center provides convenient access to care for patients seeking fertility treatment in Maine. “We ... Comprehensive Care in Portland,” said Fertility Centers of New England President and CEO, Joseph ...
(Date:5/4/2016)... ... 2016 , ... Vasont Systems, a top component content management ... the latest release of Adobe FrameMaker, Release 2015. The integration of the Vasont® ... editing and storing XML. , The VUI creates a smooth continued ...
(Date:5/3/2016)... Minnesota (PRWEB) , ... May 04, 2016 , ... ... more than 40 national and global construction firms representing the Construction Industry Safety ... have joined forces with one purpose: to inspire everyone in the industry to ...
(Date:5/3/2016)... Garden City, NY (PRWEB) , ... May 04, 2016 , ... ... as a 2016-2017 inductee into its VIP Woman of the Year Circle. She ... leading networking organization exclusively for professional women, boasting more than 850,000 members and over ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... on Denver Business Journal, patients report dissatisfaction with numerous issues related to medical ... personnel, issues with billing, and poor bedside manner from hospital staff. Commenting on ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... , May 4, 2016 ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved ... are expected to be developed in coming years. Many ... techniques. Cancer stem cell therapies are also expected to ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, ... contracted rheumatic fever, which damaged his heart. He continued ... But by June 2013, Shepherd,s heart was giving out ... death. On June 20, 2013, the Mesa, ... Artificial Heart (TAH-t). Like a heart transplant, the SynCardia ...
Breaking Medicine Technology: